Loading
A phase 1/2 trial of Lenvatinib and Doxorubicin in endometrial cancer, hepatocellular carcinoma and colorectal cancer, run by Eisai Inc., active and no longer recruiting.
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor is a phase 1/2 interventional study registered as NCT04008797 by Eisai Inc., with 301 participants enrolled, started 2019-07-11 and due to reach its primary completion in 2027-03-31. Interventions recorded: E7386, Lenvatinib, Doxorubicin and Paclitaxel.
Shares Doxorubicin, Endometrial cancer and the tag pipeline.
Shares Eisai, Lenvatinib and the tag pipeline.
Shares Eisai, Lenvatinib and the tag pipeline.
Shares Endometrial cancer, Colorectal cancer and the tag pipeline.
Shares Endometrial cancer, Colorectal cancer and the tag pipeline.
Shares Doxorubicin, Hepatocellular carcinoma and the tag pipeline.
Shares Doxorubicin, Hepatocellular carcinoma and the tag pipeline.
Shares Endometrial cancer, Colorectal cancer and the tag pipeline.